蒲公英 - 制药技术的传播者 GMP理论的实践者

 找回密码
 立即注册

QQ登录

只需一步,快速开始

使用微信帐号登录

使用微信帐号登录

查看: 721|回复: 3
收起左侧

[翻译交流] ICH Q3D 元素杂质指南 (2) ----Julia翻译

[复制链接]
药徒
发表于 2015-1-1 10:17:16 | 显示全部楼层 |阅读模式

5.4 Recommendations for Elements to be Considered in the Risk Assessment 风险评估中要考虑的要素建议

The following table provides recommendations for inclusion of elemental impurities in the risk assessment. This table can be applied to all sources of elemental impurities in the drug product.

以下表格对于风险评估中需要包括的元素杂质做出了建议。该表可以用于药品中所有来源的元素杂质。

Table 5.1: Elements to be Considered in the Risk Assessment

5.1 在风险评估中要考虑的元素

Element
元素
Class
分类
If intentionally added (al l routes)
如果有意加入(所有给药途径)
If not intentionally added
如果无意加入
Oral
口服
Parenteral
注射
Inhalation
吸入
Cd
1
Yes
Yes
Yes
Yes
Pb
1
Yes
Yes
Yes
Yes
As
1
Yes
Yes
Yes
Yes
Hg
1
Yes
Yes
Yes
Yes
Co
2A
Yes
Yes
Yes
Yes
V
2A
Yes
Yes
Yes
Yes
Ni
2A
Yes
Yes
Yes
Yes
Tl
2B
Yes
No
No
No
Au
2B
Yes
No
No
No
Pd
2B
Yes
No
No
No
Ir
2B
Yes
No
No
No
Os
2B
Yes
No
No
No
Rh
2B
Yes
No
No
No
Ru
2B
Yes
No
No
No
Se
2B
Yes
No
No
No
Ag
2B
Yes
No
No
No
Pt
2B
Yes
No
No
No
Li
3
Yes
No
Yes
Yes
Sb
3
Yes
No
Yes
Yes
Ba
3
Yes
No
No
Yes
Mo
3
Yes
No
No
Yes
Cu
3
Yes
No
Yes
Yes
Sn
3
Yes
No
No
Yes
Cr
3
Yes
No
No
Yes

5.5 Evaluation 评估

As the potential elemental impurity identification process is concluded, there are two possible outcomes:

在对潜在元素杂质进行识别后,可能会有两种结论:

1)    The risk assessment process does not identify any potential elemental impurities. The conclusion of the risk assessment and supporting information and data should be documented.

1)    风险评估未能识别出任何潜在元素杂质。风险评估的结论和支持性资料和数据要进行记录。

2)    The risk assessment process identifies one or more potential elemental impurities. For any elemental impurities identified in the process, the risk assessment should consider if there are multiple sources of the identified elemental impurity or impurities and document the conclusion of the assessment and supporting information.

2)    风险评估识别出了一个或多个潜在元素杂质。对所有识别出的元素杂质,如果该元素杂质有多个来源,要考虑进行风险评估。并记录评估的结论和支持性资料。

The applicant’s risk assessment can be facilitated with information about the potential elemental impurities provided by suppliers of drug substances, excipients, container closure systems, and manufacturing equipment. The data that support this risk assessment can come from a number of sources that include, but are not limited to:

申报人的风险评估可以利用原料药、辅料、容器密闭系统和生产设备供应商提供的关于潜在元素杂质的信息。支持风险评估的数据可以来自于许多来源,包括但不仅限于:

-     Prior knowledge;

-     之前的知识

-     Published literature;

-     出版的文献

-     Data generated from similar processes;

-     从类似工艺中产生的数据

-     Supplier information or data;

-     供应商的信息或数据

-     Testing of the components of the drug product;

-     药品组分检测

-     Testing of the drug product.

-     药品检测

During the risk assessment, a number of factors that can influence the level of the potential impurity in the drug product and should also have been considered in the risk assessment. These include but are not limited to:

在风险评估中,很多因素会对药品中潜在杂质的水平造成影响,因此也需要在风险评估中进行考虑。这包括但不仅限于:

-     Efficiency of removal of elemental impurities during further processing;

-     进一步加工中除去元素杂质的有效性

-     Natural abundance of elements (especially important for the categories of elements which are not intentionally added);

-     自然富含的元素(特别重要的是没有添加单身的杂质类别)

-     Prior knowledge of elemental impurity concentration ranges from specific sources;

-     特定来源的元素杂质浓度已有知识

-     The composition of the drug product.

-     药品组分

5.6 Summary of Risk Assessment Process 风险评估过程的总结




ICH Q3D 元素杂质指南 (2).rar (46.02 KB, 下载次数: 546)
回复

使用道具 举报

药徒
发表于 2015-1-1 11:32:02 | 显示全部楼层
感谢分享!
回复 支持 反对

使用道具 举报

药徒
发表于 2015-1-2 09:44:10 | 显示全部楼层
学习了,巴西木过节还关爱论坛,谢啦!
回复 支持 反对

使用道具 举报

发表于 4 天前 | 显示全部楼层
感谢楼主无私分享
回复 支持 反对

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×友情提示
1、无权下载附件会员可能原因:1.“待验证用户组“,请点击注册邮箱里面收到的确认邮件即可; 2.作者设定权限的,提高用户组级别即可
2、对本站的任何疑问或合作需求,请联系微信tank066,关于怎样提高用户组/积分:https://www.ouryao.com/thread-6764-1-1.html
3、注册用户在本社区发表、转载的任何作品仅代表其个人观点,不代表本社区认同其观点。
4、如果存在违反国家相关法律、法规、条例的行为,我们有权在不经作者准许的情况下删除其在本论坛所发表的文章。
5、所有网友不要盗用有明确版权要求的作品,转贴请注明来源,否则文责自负。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号 京ICP证150354号 )

GMT+8, 2019-8-18 16:22 , Processed in 0.126186 second(s), 40 queries .

Powered by Discuz! X3.2

© 2001-2012 Comsenz Inc.

返回顶部